<?xml version='1.0' encoding='utf-8'?>
<document id="30787874"><sentence text="Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia."><entity charOffset="0-11" id="DDI-PubMed.30787874.s1.e0" text="Fenofibrate" /></sentence><sentence text="P-glycoprotein (P-gp) is a membrane-bound transporter encoded by Mdr1a/Abcb1a and Mdr1b/Abcb1b genes in rodents involved in the efflux of cytotoxic chemicals and metabolites from cells" /><sentence text=" Modulation of its activity influences P-gp-mediated drug delivery and drug-drug interaction (DDI)" /><sentence text=" In the current study, we tested the effects of fenofibrate on P-gp mRNA and protein content in non-obese model of metabolic syndrome"><entity charOffset="48-59" id="DDI-PubMed.30787874.s4.e0" text="fenofibrate" /></sentence><sentence text=" Males hereditary hypertriglyceridemic rats (HHTg) were fed standard laboratory diet (STD) (Controls) supplemented with micronized fenofibrate in lower (25 mg/kg b"><entity charOffset="131-142" id="DDI-PubMed.30787874.s5.e0" text="fenofibrate" /></sentence><sentence text=" wt" /><sentence text="/day) or in higher (100 mg/kg b" /><sentence text=" wt" /><sentence text="/day) dose for 4 weeks" /><sentence text=" Liver was used for the subsequent mRNA and protein content analysis" /><sentence text=" Fenofibrate in lower dose decreased hepatic Mdr1a by 75% and Mdr1b by 85%, while fenofibrate in higher dose decreased Mdr1a by 90% and Mdr1b by 92%"><entity charOffset="1-12" id="DDI-PubMed.30787874.s11.e0" text="Fenofibrate" /><entity charOffset="82-93" id="DDI-PubMed.30787874.s11.e1" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.30787874.s11.e0" e2="DDI-PubMed.30787874.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30787874.s11.e0" e2="DDI-PubMed.30787874.s11.e1" /></sentence><sentence text=" P-gp protein content in the liver was decreased by 74% in rat treated with fenofibrate at lower dose and by 88% in rats using fenofibrate at higher dose"><entity charOffset="76-87" id="DDI-PubMed.30787874.s12.e0" text="fenofibrate" /><entity charOffset="127-138" id="DDI-PubMed.30787874.s12.e1" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.30787874.s12.e0" e2="DDI-PubMed.30787874.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30787874.s12.e0" e2="DDI-PubMed.30787874.s12.e1" /></sentence><sentence text=" These findings demonstrate for the first time that fenofibrate decreases both mRNA and protein amount of P-gp and suggest that fenofibrate could affect bioavailability and interaction of drugs used to treat dyslipidemia-induced metabolic disorders"><entity charOffset="52-63" id="DDI-PubMed.30787874.s13.e0" text="fenofibrate" /><entity charOffset="128-139" id="DDI-PubMed.30787874.s13.e1" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.30787874.s13.e0" e2="DDI-PubMed.30787874.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30787874.s13.e0" e2="DDI-PubMed.30787874.s13.e1" /></sentence><sentence text="" /></document>